Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up

Abstract

BACKGROUND We previously reported that a median of 5.6 years of intensive as compared with standard glucose lowering in 1791 military veterans with type 2 diabetes resulted in a risk of major cardiovascular events that was significantly lower (by 17%) after a total of 10 years of combined intervention and observational follow-up. We now report the full 15-year follow-up. METHODS We observationally followed enrolled participants (complete cohort) after the conclusion of the original clinical trial by using central databases to identify cardiovascular events, hospitalizations, and deaths. Participants were asked whether they would be willing to provide additional data by means of surveys and chart reviews (survey cohort). The prespecified primary outcome was a composite of major cardiovascular events, including nonfatal myocardial infarction, nonfatal stroke, new or worsening congestive heart failure, amputation for ischemic gangrene, and death from cardiovascular causes. Death from any cause was a prespecified secondary outcome. RESULTS There were 1655 participants in the complete cohort and 1391 in the survey cohort. During the trial (which originally enrolled 1791 participants), the separation of the glycated hemoglobin curves between the intensive-therapy group (892 participants) and the standard-therapy group (899 participants) averaged 1.5 percentage points, and this difference declined to 0.2 to 0.3 percentage points by 3 years after the trial ended. Over a period of 15 years of follow-up (active treatment plus post-trial observation), the risks of major cardiovascular events or death were not lower in the intensive-therapy group than in the standard-therapy group (hazard ratio for primary outcome, 0.91; 95% confidence interval [CI], 0.78 to 1.06; P = 0.23; hazard ratio for death, 1.02; 95% CI, 0.88 to 1.18). The risk of major cardiovascular disease outcomes was reduced, however, during an extended interval of separation of the glycated hemoglobin curves (hazard ratio, 0.83; 95% CI, 0.70 to 0.99), but this benefit did not continue after equalization of the glycated hemoglobin levels (hazard ratio, 1.26; 95% CI, 0.90 to 1.75). CONCLUSIONS Participants with type 2 diabetes who had been randomly assigned to intensive glucose control for 5.6 years had a lower risk of cardiovascular events than those who received standard therapy only during the prolonged period in which the glycated hemoglobin curves were separated. There was no evidence of a legacy effect or a mortality benefit with intensive glucose control. (Funded by the VA Cooperative Studies Program; VADT ClinicalTrials.gov number, .)

Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium‐glucose co‐transporter‐2 inhibitors

“…Despite the fact that hyperglycemia constitutes the primary metabolic dysregulation in T2DM, it seems that intensive blood glucose control alone is not sufficient to ameliorate cardiovascular morbidity and mortality . On the other hand, a multifactorial approach targeting additional cardiovascular risk factors, besides blood glucose, has been shown to provide significant cardioprotection .…”

MiR‐144 protects the heart from hyperglycemia‐induced injury by regulating mitochondrial biogenesis and cardiomyocyte apoptosis

“…life. 67 Therefore, the benefits of rigorous glycemic control with traditional hypoglycemic drugs are limited, although new hypoglycemic strategies (such as GLP-1 agonists and SGLT-2 inhibitors) may provide novel insight into preventing and treating diabetic complications. Targeting miR-144 may play an important role in improving the prognosis of diabetic patients.…”

Analysis of the effect of liraglutide on glycemic variability in patients with type 2 diabetes

“…CGM helps to reduce HbA1c, improve blood glucose control without increasing the risk of hypoglycemia, reduce glycemic variability, and generally improve the quality of life of diabetic patients [6]. Evidence from previous studies shows that simple control of HbA1c does not reduce the risk of diabetic macrovascular complications [42]. Compared with stable hyperglycemia, the fluctuation of blood glucose significantly increased the level of oxidative stress in diabetic patients [43].…”